Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: Mol Pharm. 2019 Jul 30;16(9):4017–4023. doi: 10.1021/acs.molpharmaceut.9b00671

Figure 2.

Figure 2.

(A): The timeline for in vivo evaluation of HP-PO materials; (B) In vivo antibacterial efficacy of HP-PO/C and HP-PO/NO polymers against P. gingivalis (n ≥ 6 mice per group) on Day 4. Dashed line indicates the detection limit. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <0.0001 compared to untreated negative control.